Advertisement

Surgery pp 1759-1772 | Cite as

Kidney Transplantation

  • Stuart J. Knechtle

Abstract

In 2002 in the United States, 431,281 patients received treatment for end-stage renal disease (ESRD), including 308,910 on dialysis and 122,374 with a functioning renal transplant.1 The prevalence of ESRD is increasing at an annual rate of 4%, down from 9% a decade ago. In 2004, there were 15,977 renal transplants performed in the United States, and two-thirds of renal transplant patients are now alive 5 years after transplantation, compared to one-third on either hemodialysis or peritoneal dialysis. The 1-year mortality of renal transplant patients is 6% for deceased donor recipients and 3% for living donor kidney recipients compared to 25% for patients treated with dialysis, reflecting the fact that transplant recipients represent a relatively healthier subset of patients with ESRD compared to dialysis patients.2 Nevertheless, the death rate on dialysis is higher than after transplantation even after adjusting for patient characteristics.3

Keywords

Renal Transplant Deceased Donor Donor Nephrectomy Chronic Allograft Nephropathy Laparoscopic Donor Nephrectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    U.S. Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Available at: www.usrds.org.Google Scholar
  2. 2.
    HHS/HRSA/SPB/DOT, UNOS, URREA. 2003 OPTN/SRTR Annual Report: Transplant Data 1993–2002. Available at: www.ustransplant.org.Google Scholar
  3. 3.
    Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001;12:1293–1296.PubMedGoogle Scholar
  4. 4.
    Pastan S, Bailey J. Dialysis therapy. N Engl J Med 1998;338:1428–1437.PubMedCrossRefGoogle Scholar
  5. 5.
    Knechtle SJ, Pirsch JD, D’Alessandro AM, et al. Renal transplantation at the University of Wisconsin in the cyclosporine era. In Terasaki PI, Cecka JM, eds. Clinical Transplants 1993. Los Angeles: UCLA Tissue Typing Laboratory; 1994;211–218.Google Scholar
  6. 6.
    Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004;4:1662–1668.PubMedCrossRefGoogle Scholar
  7. 7.
    Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235–242.PubMedCrossRefGoogle Scholar
  8. 8.
    Krmar RT, Eymann A, Ramirez JA, Ferraris JR. Quality of life after kidney transplantation in children. Transplantation 1997;64:540–541.PubMedCrossRefGoogle Scholar
  9. 9.
    Joseph JT, Baines LS, Morris MC, Jindal RM. Quality of life after kidney and pancreas transplantation: a review. Am J Kidney Dis 2003;42:431–445.PubMedCrossRefGoogle Scholar
  10. 10.
    Karam VH, Gasquet I, Delvart V, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 2003;76:1699–1704.PubMedCrossRefGoogle Scholar
  11. 11.
    Danovitch GM, Hariharan S, Pirsch JD, et al. for the Clinical Practice Guidelines Committee of the American Society of Transplantation. Management of the waiting list for cadaveric kidney transplants: report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation. J Am Soc Nephrol 2002;13:528–535.PubMedGoogle Scholar
  12. 12.
    Ramos EL, Tisher CC. Recurrent diseases in the kidney transplant. Am J Kidney Dis 1994;24:142–154.PubMedGoogle Scholar
  13. 13.
    Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999;68:635–641.PubMedCrossRefGoogle Scholar
  14. 14.
    Odorico JS, Knechtle SJ, Rayhill SC, et al. The influence of native nephrectomy on the incidence of recurrent disease following renal transplantation for primary glomerulonephritis. Transplantation 1996;61:228–234.PubMedCrossRefGoogle Scholar
  15. 15.
    Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338:1813–1821.PubMedCrossRefGoogle Scholar
  16. 16.
    Cecka JM. The OPTN/UNOS Renal Transplant Registry 2003. In Cecka JM, Terasaki PI, eds. Clinical Transplants 2003. Los Angeles: UCLA Immunogenetics Center; 2004;1–12.Google Scholar
  17. 17.
    Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966;2:662–665.PubMedCrossRefGoogle Scholar
  18. 18.
    Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735–739.PubMedGoogle Scholar
  19. 19.
    Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004;78:221–227.PubMedCrossRefGoogle Scholar
  20. 20.
    Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004;78:635–640.PubMedCrossRefGoogle Scholar
  21. 21.
    Van der Werf WJ, D’Alessandro AM, Hoffmann RM, Knechtle SJ. Procurement, preservation, and transport of cadaver kidneys. Surg Clin North Am 1998;78:41–54.PubMedCrossRefGoogle Scholar
  22. 22.
    Terasaki PI, Cho YW, Cecka JM. Strategy for eliminating the kidney shortage. In Cecka JM, Terasaki PI, eds. Clinical Transplants 1997. Los Angeles: UCLA Tissue Typing Laboratory; 1998;265–267.Google Scholar
  23. 23.
    D’Alessandro AM, Hoffmann RM, Belzer FO. Non-heart-beating donors: one response to the organ shortage. Transplant Rev 1995;9:168–176.CrossRefGoogle Scholar
  24. 24.
    Chen EP, Bittner HB, Kendall SW, Van Trigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. Crit Care Med 1996;24:1352–1359.PubMedCrossRefGoogle Scholar
  25. 25.
    Novitzky D, Wicomb WN, Cooper DKC, et al. Electrocardiographic, hemodynamic and endocrine changes occurring during experimental brain death in the chacma and baboon. J Heart Transplant 1984;4:63–69.Google Scholar
  26. 26.
    Griepp RB, Stinson EB, Clark DA, et al. The cardiac donor. Surg Gynecol Obstet 1971;133:792–798.PubMedGoogle Scholar
  27. 27.
    D’Alessandro AM, Hoffmann RM, Knechtle SJ, et al. Successful extrarenal transplantation from non-heart-beating donors. Transplantation 1995;59:977–982.PubMedCrossRefGoogle Scholar
  28. 28.
    Politano VA, Leadbetter WF. An operative technique for the correction of vesicoureteral reflux. J Urol 1958;79:932–941.PubMedGoogle Scholar
  29. 29.
    Mangus RS, Haag BW, Carter CB. Stented Lich-Gregoir uretero-neocystostomy: case series report and cost-effectiveness analysis. Transplant Proc 2004;36:2959–2961.PubMedCrossRefGoogle Scholar
  30. 30.
    Knechtle SJ. Ureteroneocystostomy for renal transplantation. J Am Coll Surg 1999;188:707–709.PubMedCrossRefGoogle Scholar
  31. 31.
    Cecka JM. The UNOS Scientific Renal Transplant Registry—10 years of kidney transplants. In Cecka JM, Terasaki PI, eds. Clinical Transplants 1997. Los Angeles: UCLA Tissue Typing Laboratory; 1998;1–14.Google Scholar
  32. 32.
    Gruessner RW, Fasola C, Benedetti E, et al. Laparoscopic drainage of lymphoceles after kidney transplantation: indications and limitations. Surgery 1995;117:288–295.PubMedCrossRefGoogle Scholar
  33. 33.
    Sankari BR, Geisinger M, Zelch M, et al. Post-transplant renal artery stenosis: impact of therapy on long-term kidney function and blood pressure control. J Urol 1996;155:1860–1864.PubMedCrossRefGoogle Scholar
  34. 34.
    D’Alessandro AM, Pirsch JD, Knechtle SJ, et al. Living unrelated renal donation: the University of Wisconsin experience. Surgery 1998;124:604–611.PubMedCrossRefGoogle Scholar
  35. 35.
    Ross LF, Rubin DT, Siegler M, et al. Ethics of a paired-kidney-exchange program. N Engl J Med 1997;336:1752–1755.PubMedCrossRefGoogle Scholar
  36. 36.
    Flowers JL, Jacobs S, Cho E, et al. Comparison of open and laparoscopic live donor nephrectomy. Ann Surg 1997;226:483–490.PubMedCrossRefGoogle Scholar
  37. 37.
    Ratner LE, Kavoussi LR, Sroka M, et al. Laparoscopic assisted live donor nephrectomy—a comparison with the open approach. Transplantation 1997;63:229–233.PubMedCrossRefGoogle Scholar
  38. 38.
    Horgan S, Benedetti E, Moser F. Robotically assisted donor nephrectomy for kidney transplantation. Am J Surg 2004;188:45S–51S.PubMedCrossRefGoogle Scholar
  39. 39.
    Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004;4:1562–1566.PubMedCrossRefGoogle Scholar
  40. 40.
    Pirsch JD, Friedman R. Primary care of the renal transplant patient. J Gen Intern Med 1994;9:29–37.PubMedCrossRefGoogle Scholar
  41. 41.
    Mihatsch MJ, Thiel G, Spichtin HP, et al. Morphological findings in kidney transplants after treatment with cyclosporine. Transplant Proc 1983;15:2821.Google Scholar
  42. 42.
    Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557–565.PubMedCrossRefGoogle Scholar
  43. 43.
    Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326–2333.PubMedCrossRefGoogle Scholar
  44. 44.
    Stoves J, Newstead CG, Baczkowski AJ, et al. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrol Dial Transplant 2004;19:2113–2120.PubMedCrossRefGoogle Scholar
  45. 45.
    Bakker RC, Hollander AA, Mallat MJ, et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003;64:1027–1034.PubMedCrossRefGoogle Scholar
  46. 46.
    Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2:807–818.PubMedCrossRefGoogle Scholar
  47. 47.
    Morath C, Mueller M, Goldschmidt H, et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004;15:1582–1588.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Stuart J. Knechtle
    • 1
  1. 1.Departments of Transplantation and SurgeryUniversity of Wisconsin Medical SchoolMadisonUSA

Personalised recommendations